Status:
COMPLETED
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Lead Sponsor:
Pfizer
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
To define what procedures were used for the diagnosis and monitoring of the treatment age-related macular degeneration (AMD). What is the effect of the Macugen, compliance with Macugen treatment, safe...
Detailed Description
no sampling
Eligibility Criteria
Inclusion
- age over 18 years old
- patients with neovascular age-related macular degeneration
- enrollment to study is fully on physician decision in compliance with current SPC
Exclusion
- Patient who did not meet indication according to SPC Macugen.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00787319
Start Date
January 1 2010
End Date
June 1 2012
Last Update
December 6 2018
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brno, Czechia, 625 00
2
Pfizer Investigational Site
Brno, Czechia, 62500
3
Pfizer Investigational Site
Olomouc, Czechia, 775 20
4
Pfizer Investigational Site
Olomouc, Czechia, 77520